Latest & greatest articles for zolpidem

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on zolpidem or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on zolpidem and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for zolpidem

1. Therapeutic efficacy of zolpidem combined with cognitive behavioral therapy (CBT) on primary insomnia (PI): a protocol of systematic review

Therapeutic efficacy of zolpidem combined with cognitive behavioral therapy (CBT) on primary insomnia (PI): a protocol of systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

2. Zolpidem

Zolpidem Top results for zolpidem - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for zolpidem The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

3. Quantitation of zolpidem in biological fluids by electro-driven microextraction combined with HPLC-UV analysis (PubMed)

Quantitation of zolpidem in biological fluids by electro-driven microextraction combined with HPLC-UV analysis In this study, for the first time, an electro-driven microextraction method named electromembrane extraction combined with a simple high performance liquid chromatography and ultraviolet detection was developed and validated for the quantitation of zolpidem in biological samples. Parameters influencing electromembrane extraction were evaluated and optimized. The membrane consisted of 2 (...) was linear over the range of 10-1000 ng/mL for zolpidem (R2 >0.9991) with repeatability ( %RSD) between 0.3 % and 7.3 % (n = 3). The limits of detection and quantitation were 3 and 10 ng/mL, respectively. The sensitivity of HPLC-UV for the determination of zolpidem was enhanced by electromembrane extraction. Finally, the method was employed for the quantitation of zolpidem in biological samples with relative recoveries in the range of 60-79 %.

Full Text available with Trip Pro

2018 EXCLI journal

4. The Association Between the Use of Zolpidem and the Risk of Alzheimer`s Disease Among Older People

The Association Between the Use of Zolpidem and the Risk of Alzheimer`s Disease Among Older People To evaluate the association between zolpidem use and the risk of Alzheimer's disease among older people.A retrospective cohort study using data from 2001 to 2011 from the National Health Insurance Research Database.Taiwan.A total of 6,922 patients aged 65 years or older enrolled from January 2002 to December 2004 (the enrollment period).Zolpidem users were identified as patients who used zolpidem (...) during the enrollment period. The index date was the date of the first zolpidem prescription. Dosage of zolpidem use was defined using cumulative defined daily dose (cDDD) based on the cumulative dosage that patients took within one year after the index date (grouped as: less than 28, 28-90, 91-180, and more than 180 cDDD).The occurrence of Alzheimer's disease was defined as the time period from the end of one year after the index date to the date of the Alzheimer's disease diagnosis. The propensity

2017 EvidenceUpdates

5. Zolpidem

Zolpidem USE OF ZOLPIDEM IN PREGNANCY 0344 892 0909 USE OF ZOLPIDEM IN PREGNANCY (Date of issue: November 2013 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Zolpidem is a short-acting non-benzodiazepine hypnotic agent which acts (...) on benzodiazepine receptors. It is indicated in the short-term treatment of patients with debilitating insomnia, or where insomnia is causing severe distress. There are few data available concerning the use of zolpidem in human pregnancy. These data do not currently suggest an increased risk of congenital malformation but are considered too limited to state that no risk exists. Associations between in-utero zolpidem exposure and increased risks of preterm delivery and low birth weight have been reported

2014 UK Teratology Information Service

6. Zolpidem: risk of drowsiness and reduced driving ability

Zolpidem: risk of drowsiness and reduced driving ability Zolpidem: risk of drowsiness and reduced driving ability - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Zolpidem: risk of drowsiness and reduced driving ability Taking zolpidem is associated with a risk of impaired driving ability the next day. Published 11 December 2014 From: Therapeutic area: Article date: May 2014 Zolpidem (Edluar, Stilnoct) is used to treat insomnia. Taking zolpidem is associated with a risk (...) of impaired driving ability the next day. To reduce this risk, advise patients: to take 10 milligrams of zolpidem at bedtime and not to take it again the same night not to drive, operate machinery, or work at heights until at least 8 hours after taking zolpidem not to take zolpidem with alcohol, illicit drugs, or other central nervous system suppressants not to drive, operate machinery or work at heights if they are still drowsy after taking Zolpidem People with liver impairment and the elderly should

2014 MHRA Drug Safety Update

7. Zolpidem tartrate - Insomnia, short-term treatment

Zolpidem tartrate - Insomnia, short-term treatment Common Drug Review CDEC Meeting — July 17, 2013; CDEC Reconsideration — September 18, 2013 Notice of CDEC Final Recommendation — September 25, 2013 Page 1 of 3 © 2013 CADTH CDEC FINAL RECOMMENDATION ZOLPIDEM TARTRATE (Sublinox – Meda Valeant Pharma Canada) Indication: Insomnia Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that sublingual zolpidem tartrate not be listed. Reason for the Recommendation: There is insufficient (...) evidence to determine if sublingual zolpidem provides comparable clinical benefit versus other hypnotics available in Canada for the treatment of acute, short-term insomnia. Background: Sublingual zolpidem is indicated for the short-term treatment and symptomatic relief of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The product monograph states that treatment with sublingual zolpidem should usually not exceed seven to 10

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

8. Intermezzo (zolpidem tartrate)

Intermezzo (zolpidem tartrate) Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Intermezzo (zolpidem tartrate) Company: Transcept Pharmaceuticals, Inc. Application No.: 022328 Approval Date: 11/23/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created

2011 FDA - Drug Approval Package

9. Zolpidem and Uncontrollable Nocturnal Eating Binges

Zolpidem and Uncontrollable Nocturnal Eating Binges Zolpidem and Uncontrollable Nocturnal Eating Binges – Clinical Correlations Search Zolpidem and Uncontrollable Nocturnal Eating Binges February 24, 2010 4 min read John Cruz Faculty peer reviewed A number of studies have shown that zolpidem ( Ambien ), the most commonly prescribed sleep-inducing medication on the market, can produce uncontrollable nocturnal eating behavior among users. Sleep related eating disorder (SRED) is characterized (...) by partial arousals from sleep to ingest food, usually within the first three hours after sleep onset, occurring one to six times per night. 1 Patients describe an “automatic” inclination to eat and an inability to return to sleep unless they eat. The foods are often high in calories and ingested in massive quantities. 2 The occurrence of zolpidem-induced nocturnal eating is probably more common than currently reported. In a New York Times article 3 entitled “Study links Ambien use to unconscious food

2010 Clinical Correlations

10. Adding zolpidem to CBT produces limited benefits in persistent insomnia

Adding zolpidem to CBT produces limited benefits in persistent insomnia Adding zolpidem to CBT produces limited benefits in persistent insomnia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adding zolpidem to CBT produces limited benefits in persistent insomnia Article Text Therapeutics Adding zolpidem to CBT produces limited benefits in persistent insomnia Statistics from Altmetric.com Question Question: Does the addition

2010 Evidence-Based Mental Health

11. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age (PubMed)

Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age The goal was to evaluate the hypnotic efficacy of zolpidem at 0.25 mg/kg per day (maximum of 10 mg/day), compared with placebo, in children 6 through 17 years of age who were experiencing insomnia associated with attention-deficit/hyperactivity disorder.An 8-week, North American, multicenter, double-blind, placebo-controlled, parallel (...) of adverse events, abnormal laboratory data, vital signs, and physical examination findings. The potential for next-day residual effects also was assessed.The baseline-adjusted mean change in latency to persistent sleep at week 4 did not differ significantly between the zolpidem and placebo groups (-20.28 vs -21.27 minutes). However, differences favoring zolpidem were observed for the older age group in Clinical Global Impression scores at weeks 4 and 8. No next-day residual effects of treatment were

2009 EvidenceUpdates Controlled trial quality: predicted high

12. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia

Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 77. 2004 Authors' objectives To provide guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. Authors' conclusions 1.1 When, after due consideration of the use of nonpharmacological measures, hypnotic

2004 Health Technology Assessment (HTA) Database.

13. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77)

Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77) Overview | Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia | Guidance | NICE Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia Technology appraisal guidance [TA77] Published date: 28 April 2004 Share Save Guidance on zolpidem and zopiclone for treating insomnia in adults. The recommendations

2004 National Institute for Health and Clinical Excellence - Technology Appraisals

14. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data

Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data Hajak G, Muller W E, Wittchen H U, Pittrow D, Kirch W CRD summary (...) This review of case reports of the abuse and dependence potential of zolpidem and zopiclone concluded that they are relatively safe. Patients with a history of abuse or dependence, or with psychiatric disease, are at increased risk of abuse or dependence. Methodological and reporting limitations mean that this review alone cannot provide robust evidence of the safety of these drugs. Authors' objectives To review the world literature for cases of dependence of zolpidem and zopiclone in order to identify

2003 DARE.

15. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. (PubMed)

Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. To evaluate the efficacy of benzodiazepines and zolpidem tartrate in chronic insomnia based on a quantitative review of literature.Articles from 1966 to 1996 were identified using MEDLINE, by a manual review of relevant journals, and from bibliographies of identified articles.Studies using randomized, double-blind, placebo-controlled, parallel or crossover designs with benzodiazepines or zolpidem in adults (...) to placebo. A combined test of effect sizes was performed on the subset of studies that reported effect size information to determine the magnitude of medication effect.A homogeneous sample of studies summarized 1894 patients treated for a median duration of 7 days. The combined test of P values demonstrated that medication was superior to placebo in all 4 outcome measures. Treatment response was moderate in magnitude by the combined test of effect sizes.Benzodiazepines and zolpidem produced reliable

1998 JAMA

16. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy

Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy Nowell P D, Mazumdar S, Buysse D J, Dew M A, Reynolds C F, Kupfer D J Authors' objectives To assess the efficacy of benzodiazepines and zolpidem for chronic insomnia. Searching MEDLINE was searched from 1966 to 1996. Current (...) but data were extracted only for the first treatment period. Specific interventions included in the review Flurazepam, estazolam, zolpidem, triazolam, quazepam, temazepam and lorazepam. These were all compared with placebo. The median duration of treatment was 7 days (range: 4 to 35). Participants included in the review People with chronic primary insomnia, in whom psychiatric and medical conditions had been ruled out as causes of insomnia. The particpants' age ranged from 18 to 65 years old

1997 DARE.

17. Zolpidem: distinct from triazolam?

Zolpidem: distinct from triazolam? Zolpidem: distinct from triazolam? Zolpidem: distinct from triazolam? Lobo B L, Greene W L Authors' objectives To compare the effectiveness and adverse effects of zolpidem with triazolam in the treatment of insomnia. Searching MEDLINE was searched from 1983 to 1996 for English language publications using the terms 'triazolam' and 'zolpidem'. Study selection Study designs of evaluations included in the review Clinical trials were included. Specific (...) interventions included in the review Zolpidem (5 to 20 mg/day) and triazolam (0.125 to 0.5 mg/day); both are short-acting sedative-hypnotics. Participants included in the review People with insomnia, including populations from general practice, psychiatric in--patients and outpatients, and the elderly. Outcomes assessed in the review Several outcomes were assessed: sleep-related outcomes such as sleep onset latency, duration and quality of sleep, number of nocturnal wakenings and nocturnal awake time

1997 DARE.